Avadel Pharmaceuticals Plc (AVDL):企業の財務・戦略的SWOT分析

GlobalDataが発行した調査報告書(DATA904C2904)
◆英語タイトル:Avadel Pharmaceuticals Plc (AVDL) - Financial and Strategic SWOT Analysis Review
◆商品コード:DATA904C2904
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年8月
◆ページ数:56
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Avadel Pharmaceuticals Plc (AVDL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Avadel Pharmaceuticals Plc (Avadel), formerly Flamel Technologies SA is a specialty pharmaceutical company, which develops and commercializes drugs for allergy, asthma, central nervous system (CNS) (narcolepsy), pain, respiratory diseases and diabetes. The company’s products are built on its proprietary polymer-based technologies: Micropump, an oral sustained release microparticles platform, LiquiTime, a Micropump – derived platform for liquid oral products, Trigger Lock, a Micropump – derived platform that enables abuse-resistant modified and controlled release formulations and Medusa that enables controlled release of injectables. It sells its products in the US, France, and Ireland. The company operates in St. Louis, Missouri, and Charlotte in the US. Avadel is headquartered in Dublin, Ireland.

Avadel Pharmaceuticals Plc Key Recent Developments

Aug 07,2018: Avadel Pharmaceuticals reports second quarter 2018 financial results
May 02,2018: Avadel Pharmaceuticals Reports First Quarter 2018 Results
Mar 22,2018: Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer
Mar 08,2018: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results
Dec 29,2017: Avadel Pharmaceuticals Issues 2018 Corporate Outlook

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Section 1 – About the Company 6
Avadel Pharmaceuticals Plc – Key Facts 6
Avadel Pharmaceuticals Plc – Key Employees 7
Avadel Pharmaceuticals Plc – Key Employee Biographies 8
Avadel Pharmaceuticals Plc – Major Products and Services 9
Avadel Pharmaceuticals Plc – History 10
Avadel Pharmaceuticals Plc – Company Statement 13
Avadel Pharmaceuticals Plc – Locations And Subsidiaries 15
Head Office 15
Other Locations & Subsidiaries 15
Section 2 – Company Analysis 17
Company Overview 17
Avadel Pharmaceuticals Plc – Business Description 18
Product Category: Akovaz 18
Overview 18
Performance 18
Product Category: Bloxiverz 18
Overview 18
Performance 18
Product Category: Vazculep 18
Overview 18
Performance 18
Product Category: License and Research Revenue 18
Performance 18
Product Category: Other 19
Performance 19
R&D Overview 19
Avadel Pharmaceuticals Plc – Corporate Strategy 20
Avadel Pharmaceuticals Plc – SWOT Analysis 21
SWOT Analysis – Overview 21
Avadel Pharmaceuticals Plc – Strengths 21
Avadel Pharmaceuticals Plc – Weaknesses 22
Avadel Pharmaceuticals Plc – Opportunities 23
Avadel Pharmaceuticals Plc – Threats 24
Avadel Pharmaceuticals Plc – Key Competitors 25
Section 3 – Company Financial Ratios 26
Financial Ratios – Capital Market Ratios 26
Financial Ratios – Annual Ratios 27
Performance Chart 30
Financial Performance 30
Financial Ratios – Interim Ratios 31
Financial Ratios – Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
Avadel Pharmaceuticals Plc, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Aug 07, 2018: Avadel Pharmaceuticals reports second quarter 2018 financial results 36
May 02, 2018: Avadel Pharmaceuticals Reports First Quarter 2018 Results 38
Mar 22, 2018: Avadel Pharmaceuticals Announces Promotion of Gregory J. Divis to Chief Operating Officer 40
Mar 08, 2018: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Results 41
Dec 29, 2017: Avadel Pharmaceuticals Issues 2018 Corporate Outlook 42
Nov 08, 2017: Avadel Pharmaceuticals Reports Third Quarter 2017 Results 44
Aug 08, 2017: Avadel Pharmaceuticals Reports Second Quarter 2017 Results 46
May 09, 2017: Avadel Pharmaceuticals Reports First Quarter 2017 Results 48
Mar 30, 2017: Avadel Pharmaceuticals Announces Planned Reduction of French Workforce 49
Mar 07, 2017: Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Results 50
Section 6 – Appendix 52
Methodology 52
Ratio Definitions 52
About GlobalData 56
Contact Us 56
Disclaimer 56

List of Tables
Avadel Pharmaceuticals Plc, Key Facts 6
Avadel Pharmaceuticals Plc, Key Employees 7
Avadel Pharmaceuticals Plc, Key Employee Biographies 8
Avadel Pharmaceuticals Plc, Major Products and Services 9
Avadel Pharmaceuticals Plc, History 10
Avadel Pharmaceuticals Plc, Subsidiaries 15
Avadel Pharmaceuticals Plc, Key Competitors 25
Avadel Pharmaceuticals Plc, Ratios based on current share price 26
Avadel Pharmaceuticals Plc, Annual Ratios 27
Avadel Pharmaceuticals Plc, Annual Ratios (Cont...1) 28
Avadel Pharmaceuticals Plc, Annual Ratios (Cont...2) 29
Avadel Pharmaceuticals Plc, Interim Ratios 31
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 34
Avadel Pharmaceuticals Plc, Recent Deals Summary 35
Currency Codes 52
Capital Market Ratios 52
Equity Ratios 53
Profitability Ratios 53
Cost Ratios 54
Liquidity Ratios 54
Leverage Ratios 55
Efficiency Ratios 55

List of Figures
Avadel Pharmaceuticals Plc, Performance Chart (2013 - 2017) 30
Avadel Pharmaceuticals Plc, Ratio Charts 32
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 33
Avadel Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 34

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Avadel Pharmaceuticals Plc (AVDL):企業の財務・戦略的SWOT分析(Avadel Pharmaceuticals Plc (AVDL) - Financial and Strategic SWOT Analysis Review)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆